StockData
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. (COCP) company profile

COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.01+0.03 (+3.30%)

Close on Nov 17, 2026Market cap $19.46MP/E –Yield –

About Cocrystal Pharma

Pharmaceutical Preparations, SIC 2834

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics targeting serious and chronic viral infections. The company applies a proprietary structure-based drug discovery platform combining computational chemistry, medicinal chemistry, X-ray crystallography, and enzymology to design direct-acting small molecule antivirals. Its research and development programs focus on RNA viruses, specifically developing product candidates for influenza, norovirus, coronaviruses, and hepatitis C.

The company operates as a single business entity with corporate headquarters located in Bothell, Washington. Clinical-stage trials and research activities for its antiviral drug candidates take place across multiple international locations, including completed and ongoing clinical studies in the United States, Australia, the United Kingdom, and Canada.

Summary of the business section of Cocrystal Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Cocrystal Pharma, Inc.
Headquarters
Bothell, WA
Address
19805 N. Creek Parkway 98011
Phone
(786) 459-1831
Employees
10, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Weinberg & Company, P.A, Los Angeles, California

Stock & identifiers

Ticker
COCP
Exchange
Nasdaq
Shares outstanding
19M, Aug 13, 2026
Public float
$11.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-12 reverse, Aug 14, 2023; 1-for-12 reverse, Oct 11, 2022; 1-for-30 reverse, Jan 24, 2018; 100-for-1, Aug 14, 2014
SEC CIK
1412486
CUSIP
19188J409
ISIN
US19188J4094
FIGI
BBG000V27360
Share class FIGI
BBG001T107W2
LEI
549300QCJ6RBUJKI7S66
EIN
35-2528215

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
James SapirsteinChief Executive Officer–
James Joseph MartinCo-CEO and CFO44,167
Sam LeePresident and Co-CEO76,355
Carol L. BrosgartDirector–
Phillip Md Et Al FrostDirector2,020,651
Anthony J. JapourDirector14,924
Fred HassanDirector1,383,009
Richard C. Pfenniger JrDirector31,400
Roger D. KornbergDirector67,878
Steven D. RubinDirector7,206,235

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025–$513.68K–$95–
FY2025
James Martin
$265.00K$265.01K–$95–
FY2025
Principal Executive Officers
$513.67K––$95–
FY2025
Sam Lee
$248.67K$248.67K–$95–
FY2024–$1.22M–$110–
FY2024
James Martin
$680.86K$610.46K–$110–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryTotalvs. prior year
James Martin
Co-Chief Executive Officer and Chief Financial Officer
$265.00K$265.00K-61%
Sam Lee
Co-Chief Executive Officer and President
$248.67K$248.67K-63%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“of December 31, 2025, we employed 10 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 26, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 19, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 19, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 6, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 16, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 18, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 19, 2019Late filingNotification of late filing
Mar 19, 2018Late filingNotification of late filing
Mar 9, 2018ListingRegistration of securities on an exchange (Form 8-A)
Mar 17, 2017Late filingNotification of late filing
Dec 1, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 27, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 24, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 1, 2014Late filingNotification of late filing
Mar 25, 2014Name changeName changed from BIOZONE PHARMACEUTICALS, INC. to Cocrystal Pharma, Inc.
Mar 20, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 8, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 12, 2013Late filingNotification of late filing
Sep 9, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 6, 2013Late filingNotification of late filing
Mar 18, 2013Late filingNotification of late filing
May 15, 2012Late filingNotification of late filing
Mar 30, 2012Late filingNotification of late filing
Nov 14, 2011Late filingNotification of late filing
Aug 22, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 17, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 15, 2011Late filingNotification of late filing
Jul 7, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 19, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 16, 2011Late filingNotification of late filing

See a number that looks wrong?